3.365 USD
-0.06 (-1.9%)
Last: Jan 30, 2026, 11:48 AM
ChartMill assigns a Buy % Consensus number of 76% to MRVI. The Buy consensus is the weighted average rating of the current analysts ratings.
- Analysts have set a mean price target forecast of 4.01. This target is 19.08% above the current price.
- MRVI was analyzed by 17 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about MRVI.
- In the previous month the buy percentage consensus was at a similar level.
- MRVI was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-15 | Wells Fargo | Maintains | Overweight -> Overweight |
| 2025-08-12 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-05-13 | Baird | Maintains | Neutral -> Neutral |
| 2025-05-13 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-03-25 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-03-21 | UBS | Maintains | Neutral -> Neutral |
| 2025-03-03 | B of A Securities | Maintains | Buy -> Buy |
| 2025-02-26 | Baird | Downgrade | Outperform -> Neutral |
| 2024-12-05 | Goldman Sachs | Downgrade | Neutral -> Sell |
| 2024-11-14 | Wolfe Research | Initiate | Peer Perform |
| 2024-11-08 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-11-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-08 | Baird | Maintains | Outperform -> Outperform |
| 2024-10-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-08-27 | Wells Fargo | Initiate | Overweight |
| 2024-08-16 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-08-13 | Morgan Stanley | Downgrade | Overweight -> Equal-Weight |
| 2024-08-08 | UBS | Maintains | Neutral -> Neutral |
| 2024-08-08 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-07-09 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-05-09 | Baird | Maintains | Outperform -> Outperform |
| 2024-04-10 | Craig-Hallum | Initiate | Buy |
| 2024-02-23 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-02-23 | Stifel | Maintains | Buy -> Buy |
| 2023-12-12 | B of A Securities | Upgrade | Neutral -> Buy |
| 2023-11-09 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2023-11-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-08-09 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2023-08-08 | Deutsche Bank | Maintains | Buy -> Buy |
| 2023-08-08 | Keybanc | Downgrade | Overweight -> Sector Weight |
MARAVAI LIFESCIENCES HLDGS-A / MRVI FAQ
What is the average price target for MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
17 analysts have analysed MRVI and the average price target is 4.01 USD. This implies a price increase of 19.08% is expected in the next year compared to the current price of 3.365.
Can you provide the consensus rating for MARAVAI LIFESCIENCES HLDGS-A stock?
The consensus rating for MARAVAI LIFESCIENCES HLDGS-A (MRVI) is 76.4706 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts cover MARAVAI LIFESCIENCES HLDGS-A (MRVI) stock?
The number of analysts covering MARAVAI LIFESCIENCES HLDGS-A (MRVI) is 17.